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Abstract: Background: Existing standardized biofilm assays focus on simple mono-species or
bacterial-only models. Incorporating Candida albicans into complex biofilm models can offer a
more appropriate and relevant polymicrobial biofilm for the development of oral health products.
Aims: This study aimed to assess the importance of interkingdom interactions in polymicrobial oral
biofilm systems with or without C. albicans, and test how these models respond to oral therapeutic
challenges in vitro. Materials and Methods: Polymicrobial biofilms (two models containing 5 and
10 bacterial species, respectively) were created in parallel in the presence and absence of C. albicans
and challenged using clinically relevant antimicrobials. The metabolic profiles and biomasses of
these complex biofilms were estimated using resazurin dye and crystal violet stain, respectively.
Quantitative PCR was utilized to assess compositional changes in microbial load. Additional assays,
for measurements of pH and lactate, were included to monitor fluctuations in virulence “biomarkers.”
Results: An increased level of metabolic activity and biomass in the presence of C. albicans was
observed. Bacterial load was increased by more than a factor of 10 in the presence of C. albicans.
Assays showed inclusion of C. albicans impacted the biofilm virulence profiles. C. albicans did not
affect the biofilms’ responses to the short-term incubations with different treatments. Conclusions:
The interkingdom biofilms described herein are structurally robust and exhibit all the hallmarks of a
reproducible model. To our knowledge, these data are the first to test the hypothesis that yeasts may
act as potential “keystone” components of oral biofilms.
Keywords: fungal–bacterial interactions; oral biofilm; high-throughput; polymicrobial; antimicro-
bials; biofilm models
1. Introduction
Biofilms are an integral part of a healthy oral microbiome, with a diverse range of
constituents [1]. In dysbiotic states, such as lowered pH or increased plaque accumulation
leading to host inflammation, these biofilms can cause a range of diseases, from dental
caries, a disease highly prevalent in children, to periodontal disease in adulthood and
denture-related infections in the elderly [2]. It has been projected that 90% of the population
will need some form of disease intervention in the oral cavity throughout their life, and
the World Health Organization defines oral diseases as the most common preventable
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disease burden worldwide [3–5]. This extensive and preventable occurrence of oral diseases
highlights the need for further research and accurate clinical treatments for their prevention.
A wide range of bacterial colonizers have been confirmed within a healthy oral cavity
through advanced molecular techniques such as next generation sequencing. From such
studies, a number of key bacterial genera appear to be conserved amongst individuals,
including Streptococcus, Veillonella, Granulicatella, Actinomyces, Fusobacterium and various
anaerobic bacteria [6–8]. In addition, Candida and other fungal species have also been
identified as colonizers in studies focusing on the mycobiome in the oral cavity [9–12].
Indeed, it is well documented that at mucosal surfaces, C. albicans has the ability to act as a
symbiont in healthy individuals, transitioning to a pathobiont or dysbiotic entity in certain
hosts under some conditions [13,14]. This is similarly the case for the oral cavity [15–17],
whereby C. albicans is commonly associated with known constituents of the oral microbiome
in both healthy and diseased individuals [18–21]. Despite this confirmation, many studies
lack a crucial fungal element within in vitro biofilm testing, leading to unrealistic challenges
of models designed for the oral cavity [22–24]. This lack of interkingdom polymicrobiality
limits the advancement and improvement of commercial biofilm testing of novel agents
in vitro.
As discussed above, studies have confirmed the presence of numerous fungal species
within oral biofilms; however, their role is still disputed. Common commensal plaque
constituents, such as Streptococcus and Actinomyces species, have been shown to grow
synergistically with C. albicans, increasing biofilm production [25,26]. While this may indi-
cate an increase in pathogenicity when Candida is present within plaque, strengthened by
known interactions with periodontal pathogen Porphyomonas gingivalis (for example, [21]),
C. albicans has been identified in healthy individuals, suggestive the organism possesses
a symbiotic phenotype [9]. Indeed, the ability of C. albicans to shift from a “commensal
state” as a yeast cell to a “pathogenic” hyphae-forming phenotype under certain conditions
also impacts its invasiveness at mucosal sites such as the oral cavity [27,28]. Alternatively,
antagonistic interkingdom interactions have also been described whereby pathogens such
as Fusobacterium nucleatum can inhibit of hyphae formation in C. albicans, which leads
to reduced virulence attributes of both organisms [29]. From this, it is evident that the
interkingdom interactions in the oral cavity can both be beneficial or detrimental to the
oral micro- and/or mycobiomes.
Clear evidence suggests that bacteria such as P. gingivalis can act as “keystone pathogens”
in periodontitis [30]. However, Janus and colleagues (2016) have proposed that C. albicans
acts as a “keystone commensal” given its close interactions with “health-associated” bac-
teria, offering a scaffold effect and influence on the local environment within the biofilm
through pH buffering [15]. C. albicans has been found within and implicated in all aspects of
oral disease from caries, periodontitis and denture stomatitis. Close association with Strep-
tococcus mutans in caries patients has caused researchers to link Candida to a more severe
cariogenic lesion in children [31]. Similarly, Candida spp. have been heavily implicated in
soft tissue infections, such as denture stomatitis and periodontitis with its ability to adhere
to and invade epithelial cells [32,33]. These implications may be substantial; however,
the presence of C. albicans alone does not indicate disease, and so environmental factors
are likely significant. The “ecological plaque hypothesis” focuses upon the relationships
between the organisms present and the environment within the oral cavity, with disease
occurring upon a dysbiotic “event” [34]. Therefore, physiological interventions alongside
microbial control may offer beneficial therapeutics [35]. Ultimately, this may indicate that
a role for C. albicans in health and disease is more closely linked to the interactions and
overall environment of the oral cavity, as opposed to fungal burden leading to disease.
Thus, including C. albicans in in vitro model systems is essential to truly understanding
interkingdom relationships within these polymicrobial biofilms.
One aim of this study was to determine whether the inclusion of C. albicans within
two oral models, a hard-tissue and soft-tissue biofilm, leads to changes in biofilm “profiles”
and/or pathogenic “signatures.” Specifically, biomass quantification, metabolic profile,
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composition and ultrastructure of the biofilms were assessed with or without C. albicans.
Secondly, an aim was to investigate whether inclusion of this organism will impact the
biofilms’ responses to conventional therapeutics. To the authors knowledge, this is the
first study to assess the importance of including a fungus in such in vitro systems to model
interkingdom oral biofilms and in particular test the “keystone commensal” hypothesis
postulated by Janus et al. (2016) previously [15]. Moving forward, results from this study
will hopefully inform us of the importance of mimicking fungal–bacterial interactions
in vitro for antimicrobial testing, particularly in a commercial setting.
2. Materials and Methods
All biofilm studies reported in this work were carried out in accordance with the
minimum information guidelines specified for biofilm formation in microplates [36].
2.1. Growth and Standardization of Bacteria
The biofilm models used within this study have previously been published by the
research group [24,37,38]. These models were created to encompass the well-documented
main etiological agents of the oral diseases they are based upon [39,40]. To highlight
the natural evolution of disease, sequential addition of the organisms was employed.
Initial colonizers were used to attach to the surface of the plate; intermediate colonizers
allowed bridging between organisms; pathogenic colonizers were added as a final stage of
disease [41].
All pure culture organisms were stored prior to use in Microbank™ beads (Pro-
lab Diagnostics, Birkenhead, UK) at −80 ◦C. Prior to culture preparation, organisms
were revived from frozen stocks as follows: Streptococcus mitis NCTC 12261, Streptococcus
intermedius ATCC 27335, Streptococcus oralis ATCC 35037, Streptococcus mutans ATCC 25,175
and Aggregatibacter actinomycetemcomitans DSMZ 1123 were grown and maintained at 37 ◦C
5% CO2 on Colombia blood agar (CBA (Oxoid, Basingstoke, UK)). C. albicans 3153A was
maintained on Sabouraud’s dextrose agar (Oxoid, UK) at 30 ◦C under aerobic conditions
for 48 h. Fusobacterium nucleatum ATCC 1096, F. nucleatum ssp. vincentii ATCC 49256,
Actinomyces naeslundii ATCC 19039, Veillonella dispar ATCC 27335, Prevotella intermedia
ATCC 25,611 and Porphyromonas gingivalis W83 were maintained at 37 ◦C on fastidious
anaerobic agar (FAA (Lab M, Bury, UK)) in an anaerobic chamber (Don Whitley Scientific
Limited, Bingley, UK) with an atmosphere of 85% N2, 10% CO2 and 5% H2 for 48 h or 72
h for strict anaerobes. All media and agar to be used for anaerobes were deoxygenated
for 24 h prior to use. Lactobacillus casei DSMZ 20,011 was grown and maintained on MRS
agar (Oxoid, UK) in 37 ◦C 5% CO2. Aerobic organisms were then stored at 4 ◦C for a
maximum of 2 weeks prior to propagation, while anaerobic organisms were stored within
the anaerobic chamber for 1 week prior to being re-streaked.
Culture broths for propagation were prepared as follows: Overnight (16–18 h) broths
of S. mitis, S. intermedius, S. oralis, S. mutans and A. actinomycetemcomitans were grown
statically in 10 mL tryptic soy broth (TSB, Sigma-Aldrich, Gillingham, UK) at 37 ◦C 5%
CO2. C. albicans was grown for 16–18 h in 10 mL yeast peptone dextrose (YPD, Sigma-
Aldrich, UK) at 30 ◦C in an orbital benchtop shaker at 200 rpm, 20 mm orbital diameter
(IKA KS 4000 I control, IKA®-Werke GmbH & Co., Staufen, Germany). P. gingivalis,
F. nucleatum and F. nucleatum ssp. vincentii were propagated in 10 mL deoxygenated
Schaedlers anaerobic broth (Oxoid, UK). V. dispar, A. naeslundii, and P. intermedia were
grown in 10 mL of brain heart infusion broth, (BHI, Sigma-Aldrich, UK) in anaerobic
chamber 37 ◦C, 85% N2, 10% CO2 and 5% H2. L. casei was grown in 10 mL of MRS broth
(Oxoid, UK), 37 ◦C, 5% CO2. Anaerobic cultures were grown for 48 h as necessary, then
pelleted by centrifugation (VWR megastar 1.6R, VWR International GmbH. Darmstadt,
Germany (3000× g)). Pellets were then washed via resuspension twice in phosphate
buffered saline (PBS, Sigma-Aldrich, UK). Following washing the cells were standardized
to 1 × 108 cells/mL using a spectrophotometer for bacteria and via haemocytometer
counting for Candida (cell count× dilution factor× volume of square = colony forming unit
Microorganisms 2021, 9, 59 4 of 23
[CFU/mL). Previously, to determining accurate absorbance readings at 550 nm that equate
to 1 × 108 cells/mL for the bacteria, the Miles and Misra colony counting technique was
employed [42] by serially diluting pure colonies to determine the correct absorbance per
organism. Streptococcus spp., V. dispar and L. casei were read at an OD of 0.5. A. naeslundii, F.
nucleatum, F. nucleatum ssp. vincentii, P. gingivalis, P. intermedia and A. actinomycetemcomitans
were read at an OD of 0.2.
2.2. Development of Multi-Species Biofilms
Bacteria and fungi were standardized (1 × 107 CFU/mL) in an equal volume of
Roswell Park Memorial Institute-1640 (RPMI) with Todd Hewitt Broth (THB) supplemented
with 0.01 mg/mL hemin and 0.2 µL/mL (2 µg/mL) menadione in a similar manner as
previously described [43]. These preparations were generated by diluting bacteria 10×
after the initial standardization following washing and diluting to appropriate OD. Candida
dilution was carried out using the CFU/mL calculated previously and applying the C1V1
= C2V2 calculation. Biofilms formed to create the oral biofilm models were grown directly
in a clear flat bottomed 96 well polystyrene plate (Corning, New York, US) using a 200 µL
inoculation volume unless stated otherwise. Medium was replaced every 24 h using a
multichannel pipette, carefully at a 45◦ angle and at the same point within the plate (bottom
left of the well) to limit unnecessary disruption of the biofilm.
2.3. Hard Tissue (HT)—Caries Associated Biofilm
Initial pioneer species C. albicans and S. mutans were standardized together within an
RPMI/THB aliquot and matured in 96 well flat bottom plates using 200 µL per well for
24 h in 5% CO2. The supernatant was then removed as described above and an RPMI/THB
aliquot containing a mixture of standardized F. nucleatum, A. naeslundii, V. dispar and L.
casei was added and incubated in the same conditions for 4 days. RPMI/THB medium was
replaced daily to produce a 6-species biofilm. The supernatant was then removed, and
biofilms were ready to be used for downstream experiments. In biofilms omitting Candida,
the same sequential addition was used minus C. albicans in the initial step.
2.4. Soft Tissue (ST)—Periodontitis/Denture Stomatitis Associated Biofilm
Initial pioneer species C. albicans, S. oralis, S. mitis and S. intermedius were standardized
together in an RPMI/THB aliquot and matured in 96 well flat bottom plates using 200 µL
per well for 24 h in 5% CO2 The supernatant was removed as described above and an
RPMI/THB aliquot containing a mixture of standardized F. nucleatum, F. nucleatum ssp
vincentii, A. naeslundii and V. dispar was added and incubated in an anaerobic cabinet (85%
N2, 10% CO2, 5% H2, (Don Whitley Scientific Limited, UK)) for 24 h. The supernatant
was again removed and a deoxygenated RPMI/THB aliquot containing standardized P.
gingivalis, P. intermedia, and A. actinomycetemcomitans added in an anaerobic cabinet. The
medium was replaced daily for 4 days to produce an 11 species biofilm. The supernatant
was then removed, and biofilms were ready to be used for downstream experiments.
As above, in biofilms omitting Candida, the same sequential addition was used minus C.
albicans in the initial step.
2.5. Testing of Oral Models
To establish the importance of incorporating C. albicans into the biofilms, assessment
of metabolic testing alongside biomass determination was carried out. Additionally, qPCR
was utilized to assess changes in bacterial load and composition. Scanning electron mi-
croscopy was also used to determine architectural differences. Changes in pathogenesis
were also estimated by measuring fluctuations in pH, reactive oxygen species (ROS) and
enzyme levels. To further define the differences in the biofilms with or without C. albicans,
models were subjected to treatment as described below.
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2.6. Metabolic Analysis of Oral Biofilms
Biofilms were analyzed for metabolic activity using alamarBlue™ cell viability dye
(Invitrogen, Inchinnan, UK). Once matured or after treatment and neutralization, alamar-
Blue™ was added at 10% well volume in RPMI/THB (e.g., 20 µL per 200 µL RPMI/THB)
using a multichannel pipette in dark conditions. Plates were then incubated at 37 ◦C
5% CO2, with a change from blue to pink indicative of a reduction in the fluorogenic dye
resazurin to resorufin by enzymes involved in normal cellular respiration. The color change
was read when the growth control reached a bright pink color to allow this to be used as
a positive control or the latest after 3 h, depending on which occurred first. 100 µL from
each well was transferred to a fresh 96 well flat bottom microtiter plate and top read using
fluorescence 530/590 nm (FLOUstar™, BMG lab tech, Aylesbury, UK). A negative sterility
control was also used on the same plate whereby no biofilm growth was initiated to use as
a blank to normalize the fluorescence by an average of this value. In cases of treatment,
a positive growth control (e.g., minus treatment) was included as a 100% growth value,
to allow metabolic activity to be calculated as a percentage based on this growth control.
All experiments assessing metabolic activity were completed using biofilms in triplicate or
quadruplicate on three separate occasions.
2.7. Assessment of Oral Biofilms Biomass
The biomass of the biofilms were quantified using a crystal violet stain. Post metabolic
assessment, spent cell viability dye was removed carefully with the pipette tip placed at the
bottom left of the well, then biofilms were washed once with PBS and airdried overnight at
RT. A stock solution of 1% crystal violet (CV) (Sigma-Aldrich, UK) was made using ddH2O
and diluted to 0.05% for use. A total of 100 µL of 0.05% CV solution was added to each well
and incubated at RT for 30 min. CV was then removed using a multichannel pipette, and
biofilms washed twice using ddH2O removing excess dye. To limit unnecessary disruption
of the biofilm, the wash steps were achieved by placing the pipette tip at 45º angle at the
same point within the plate (bottom left of the well). Following wash steps, a volume of
100 µL of 100% ethanol was used to de-stain the biofilm; following addition to the biofilms
(at the same point within the plate as above e.g., bottom left of the well), this suspension
was mixed well with a pipette five times and 75 µL transferred to a fresh 96 well flat
bottom microtiter plate for measurement. Biomass was quantified by reading absorbance
at 570 nm (FLOUstar™, BMG lab tech, UK). A negative sterility control was also used on
the same plate whereby no biofilm growth was initiated to use as a blank to normalize the
absorbance by an average of this value. In cases of treatment, a positive growth control
was included, to be used as an untreated comparison. All experiments assessing biomass
were completed using biofilms in triplicate or quadruplicate on three separate occasions.
2.8. Quantitative Analysis of Biofilm Composition
Real-time quantitative PCR (qPCR) was performed to enumerate the relative compo-
sition of the biofilms. Briefly, bacterial biofilms were removed by using a pipette tip in
150 µL PBS to detach the cells from the 96-well plate and added to 850 µL PBS for further
use. Initially, following removal of these biofilms using the pipette, a plate was stained
with CV to ensure no biomass remained. Indeed, using this methodology, minimal biomass
remained on the plate after removal. The homogenized suspension was then used for
DNA extraction using the QIAamp DNA Mini Kit (Qiagen, Manchester, UK), following
manufacturer’s instructions. Following on from this, 1 µL of extracted DNA was added to a
mastermix containing 10 µL SYBR® GreenER™, 7 µL UV-treated RNase-free water and 1 µL
of 10 µM forward/reverse primers for each bacterial genus or species. The primers used
were previously published, as listed elsewhere [24,38], and are shown in Table 1. Three
independent replicates from each parameter were analysed in duplicate using StepOne-
Plus Real-Time PCR system and StepOnePlus software (ThermoFisher, Loughborough,
UK). PCR thermal profiles were as follows, holding stage at 50 ◦C for 2 min, followed by
denaturation stage at 95 ◦C for 5 min and then 40 cycles of 95 ◦C for 3 s and 60 ◦C for 30 s.
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Samples were quantified to calculate the colony forming equivalent (CFE) based upon
a previously established standard curve of bacterial colony forming units ranging from
1 × 103 to 108 CFU/mL. The R2 values for these standard curves ranged from 0.984 to
0.997. All samples from each triplicate experiment were run in duplicate within the qPCR
plate and used as a mean to limit fluorescence variation. Two duplicate control samples
containing mastermix only were used to assess for contamination.
Table 1. Primers used in the study.
Primer Sequence (5′-3′) References
A. actinomycetemcomitans F-GAACCTTACCTACTCTTGACATCCGAAR-TGCAGCACCTGTCTCAAAGC [44]
A. naeslundii F-GGCTGCGATACCGTGAGGR-TCTGCGATTACTAGCGACTCC [45]
C. albicans F- CTCGTAGTTGAACCTTGGGCR- GGCCTGCTTTGAACACTCTA [38]
F. nucleatum spp. F-GGATTTATTGGGCGTAAAGCR-GGCATTCCTACAAATATCTACGAA [46]
P. intermedia F-CGGTCTGTTAAGCGTGTTGTGR-CACCATGAATTCCGCATACG [44]
P. gingivalis F-GGAAGAGAAGACCGTAGCACAAGGAR-GAGTAGGCGAAACGTCCATCAGGTC [47]
Streptococcus spp. F-GATACATAGCCGACCTGAGR-CCATTGCCGAAGATTCC [46]
V. dispar F-CCGTGATGGGATGGAAACTGCR-CCTTCGCCACTGGTGTTCTTC [48]
L. casei F-TGCACTGAGATTCGACTTAAR-CCCACTGCTGCCTCCCGTAGGAGT [49]
16S F-CGCTAGTAATCGTGGATCAGAATGR-TGTGACGGGCGGTGTGTA [50]
18S F-CTCGTAGTTGAACCTTGGGCR-GGCCTGCTTTGAACACTCTA [51]
2.9. Visualization of Oral Biofilms
Scanning electron microscopy (SEM) was performed on intact biofilms grown on
13mm2 coverslips (Thermofisher, UK). Following maturation and treatment, biofilms were
washed three times with PBS with the pipette tip placed in the bottom left of the well to
avoid disruption of the biofilm. Following washing, fixative solution was then added to the
biofilms containing 2% paraformaldehyde, 2% glutaraldehyde, 0.15 M sodium cacodylate
and 0.15% w/v alcian blue (pH 7.4) and fixed overnight. A 0.15 M sodium cacodylate buffer
was then used as a storage buffer and samples kept at 4 ◦C until processing. SEM processing
of biofilm samples followed a series of fixation and dehydration steps preceding a final
gold sputter coating allowing visualization as described elsewhere [52]. Briefly, samples
were washed 3 × 5 min with 0.15 M sodium cacodylate to ensure glutaraldehyde removal.
Samples were then treated with 1% osmium tetroxide solution containing 0.15 M sodium
cacodylate (1:1) and incubated in a fume hood for 1 h. Samples were rinsed 3 × 10 min
with distilled water and then treated with 0.5% uranyl acetate and incubated in the dark for
1 h. Uranyl acetate was removed from the samples and rinsed with water before a series of
dehydration steps were carried out. 2 × 5 min rinses of 30, 50, 70 and 90% alcohol were
followed by 4 × 10 min rinses of absolute and dried absolute alcohol. Critical point drying
was then undertaken by soaking the biofilms in hexamethyldisilazane for 2 × 5 min rinses.
Samples were then placed in a desiccator overnight to allow samples to be thoroughly
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dried. The specimens were then mounted and sputter-coated with gold in an argon filled
chamber, and then viewed under a JEOL JSM-6400 scanning electron microscope.
2.10. Assays to Assess Pathogenicity of the Oral Biofilms
Supernatants were collected from the biofilms on the final day of growth, centrifuged
in microcentrifuge tubes at 8000× g for 5 min. Aliquots of the supernatant were used
fresh for pH testing (FiveEasy meter and InLab® micro (Mettler Toledo, Columbus, OH,
USA)) and the remainder frozen at −80 ◦C until further use for remaining assays. Biofilms
were tested using lactate assay kit as per kit instructions (Sigma-Aldrich, UK). Briefly,
20 µL of sample was mixed with a master mix (1:1) consisting of assay buffer, enzyme
mix and lactate probe in a 23:1:1 ratio. A standard curve was also prepared. Mixture was
incubated in the dark for 15 min at room temperature and read at 570 nm (FLOUstar™,
BMG Labtech, UK). ROS assessment was carried out using a superoxide determination kit
as per manufacturers instruction, with the exception of incubation time (Sigma-Aldrich,
UK). Briefly, 20 µL of sample was added to a 96-well microtiter plate and mixed with
200 µL of diluted WST working solution and 20 µL of diluted enzyme working solution.
This was then incubated at 37 ◦C for 24 h and absorbance read at 450 nm (FLOUstar™,
BMG Labtech, UK). Appropriate blanks were used according to instruction of the kit. Each
replicate sample were run in duplicate. Superoxide dismutase enzyme from Escherichia coli
(Sigma-Aldrich, UK) was used to achieve an inhibition standard curve to allow units/mL to
be calculated from percentage inhibition. Protease release was determined using a protease
fluorescent detection kit following manufacturer’s instructions (Sigma-Aldrich, UK). In
a microcentrifuge tube, 10 µL of each sample was used neat and mixed with 20 µL of
incubation buffer and 20 µL of fluorescent labelled casein and incubated for 1 h at 37 ◦C in
the dark. A total of 150 µL of 0.6N Trichloroacetic acid solution was then added and mixed
to precipitate larger fragments which have not been cleaved. After incubation at 37 ◦C
for 30 min in the dark, the tubes were centrifuged for 10 min at 3000× g. The supernatant
was transferred to a black 96-well microtiter plate and read as a fluorescent measurement
at 485/535 nm, excitation/emission (FLOUstar™, BMG Labtech, UK). Serine protease
trypsin was used as a control to generate a standard curve and negative controls used as
appropriate.
2.11. Treatment of Oral Biofilms
To determine if the inclusion of C. albicans affected the susceptibility or tolerance of the
oral biofilms to treatment, a range of both therapeutic challenges were used. The following
concentrations and treatment preparations were used; 0.2% chlorhexidine gluconate (CHX,
(Sigma-Aldrich, UK)) was used to mimic standard daily mouth-washing as a gold standard
used within the dentistry industry and was used to mimic standard daily mouth wash-
ing [53], 4% Ethylenediaminetetraacetic acid (EDTA, (Sigma-Aldrich, UK)) a commonly
used irrigant in endodontic treatments was used [54]. Potassium iodine at 1% served
to mimic disinfection protocols in dentistry procedures [55]. Miconazole, an ergosterol
inhibitor and anti-fungal agent was used at a concentration of 40 µg/mL based on previous
studies [56]. All solutions were prepared fresh in sterile H2O prior to experimental use.
For the treatment studies, biofilms were grown in 96-well microtiter plates then
washed three times to remove non-adherent cells as above. A total of 200 µL of testing
compound was pipetted onto the biofilms at a 45◦ at the side of the well to avoid any
disturbance to the biofilm. Biofilms were incubated at room temperature for 10 min. This
incubation time was selected so that it partially mimicked the short treatment for oral
health products, but long enough to ensure efficient action of the therapeutics, especially
since this model utilized a static system (e.g., without combinative physical debridement).
Following incubation, treatments were neutralized using 200 µL Dey Engley neutralizing
broth (Sigma-Aldrich, UK) for 15 min and then washed once more with PBS using the
same procedure as discussed above. A total of four wells within the microtiter plate were
then used for metabolic analysis and biomass determination per experiment, while three
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others were used solely for biomass removal and DNA extraction for qPCR analyses. All
experiments assessing metabolic activity were completed using biofilms in triplicate or
quadruplicate on three separate occasions.
2.12. Statistical Analysis and Data Presentation
Graph production, data distribution and statistical analysis were performed using
GraphPad Prism (version 8; La Jolla, CA, USA). After assessing whether data conformed to
a normal distribution, unpaired Mann–Whitney t tests were used to investigate significant
differences between independent groups of data. A Kruskal-Wallis was carried out with
Dunn’s post-test analysis to assess differences between biofilms under treatment. Statistical
significance was achieved upon p < 0.05.
3. Results
3.1. Metabolic, Biomass and Compositional Profiles of Oral Biofilm Models with or without C. albicans
Multi-species biofilms were grown in parallel in the presence or absence of C. albicans
to determine the change to the overall metabolic rate and biomass of biofilms following
incorporation of Candida (Figure 1). The results indicate that both metabolic activity and
biomass were significantly increased upon the inclusion of C. albicans in both hard (HT)
and soft tissue (ST) biofilms (p < 0.001). The fluorescence readings illustrating metabolic
activity showed that HT biofilms increased by 2.8-fold, the mean output reading went from
~16,000 to ~45,000 Au (Figure 1A). Meanwhile, ST biofilms showed a 1.8-fold increase in
metabolic activity when C. albicans was present, increasing from ~27,000 to ~50,000 Au. In
a similar trend, the biomasses of the oral biofilm models were also significantly increased
when Candida was included; HT biofilms increased almost 4-fold from an average O.D. of
~0.5 to ~2.0; and ST associated biofilm increased from ~0.8 O.D. to ~2.0, a 2.5-fold increase
(Figure 1B). Overall, this data highlighted a thicker biofilm which is more metabolically
active when C. albicans was present, in both models tested.
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Figure 1. Metabolic and biomass profiles of hard tissue (HT) and soft tissue (ST) biofilms plus or minus 
Candida albicans. Biofilms were grown in 96 well microtiter plates. Metabolic activity (A) was assessed 
using Alamar blue™ rezasurin dye to determine respiration rates, and biomass (B) was assessed using 
crystal violet as a disclosing stain to interpret differences in biofilm formation. Biofilms were grown and 
assayed in triplicate or quadruplicate on three separate occasions (a total of n = 11 biofilms from three 
separate experiments). Data represented as mean ± SD. Statistical analysis performed using an unpaired 
Mann–Whitney t-test to compare differences in mean (*** p < 0.001). 
Crystal violet staining is unable to differentiate between cell numbers and composi-
tion and is just an overall estimate of the biomass of all components (cells, eDNA and 
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A significant increase of more than one log was seen in the HT biofilm, ~6.0 × 107 CFE/mL, 
which increased to ~1.5 × 109 CFE/mL when C. albicans was included. Similarly, an increase 
from ~1.8 × 108 to ~9.0 × 108 CFE/mL was observed in ST-associated biofilms. The fungal 
Figure 1. Metabolic and biomass profiles of hard tissue (HT) and soft tissue (ST) biofilms plus or
minus Candida albicans. Biofilms were grown in 96 well microtiter plates. Metabolic activity (A)
was assessed using Alamar blue™ rezasurin dye to determine respiration rates, and biomass (B)
was assessed using crystal violet as a disclosing stain to interpret differences in biofilm formation.
Biofilms were grown and assayed in triplicate or quadruplicate on three separate occasions (a total of
n = 11 biofilms from three separate experiments). Data represented as mean ± SD. Statistical analysis
performed using an unpaired Mann–Whitney t-test to compare differences in mean (*** p < 0.001).
Crystal violet staining is unable to differentiate between cell numbers and compo-
sition and is just an overall estimate of the biomass of all components (cells, eDNA and
extracellular matrix). Therefore, quantitative PCR was used to determine bacterial and
fungal load using 16S and 18S primers (Figure 2A). Additionally, genus and species-specific
primers detailed in Table 1 were also used to calculate overall percentage composition in HT
(Figure 2B) and ST biofilms (Figure 2C). Results show that bacterial load was increased in
both HT and ST biofilm models when C. albicans was present (both p < 0.001). A significant
increase of more than one log was seen in the HT biofilm, ~6.0 × 107 CFE/mL, which
increased to ~1.5 × 109 CFE/mL when C. albicans was included. Similarly, an increase from
~1.8 × 108 to ~9.0 × 108 CFE/mL was observed in ST-associated biofilms. The fungal load
present in each of the biofilms was also assessed. Results showed that ~4.4 × 107 CFE/mL
and ~6.2 × 106 CFE/mL of C. albicans were detected in HT and ST, respectively.
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± SD; n = 3 i three indepen ent experiments. A Mann–Whitney t est was carried out to assess diff rences b tween means
of bacterial load in biofilms c ntaining C. albicans compared to without (*** p < 0.001).
ll i on from total bacterial load as essment, compositional analysis of the
biofilms was done. In the HT biofilm, Figure 2B, the key ch nge ssociated with the in-
clusion of C. albicans was the reduction of S. mutans from ~43.1% in biofilms without C.
albicans, to ~29.0% in biofilms with C. albicans. However, this compositional change was
not due to a reduction in microbial burden of S. mutans, which increased from 7.12 × 106
to 1.04 × 108 CFE/mL. A. naeslundii and L. casei also reduced in proportion, following
inclusion of C. albicans, decreasing from ~7.8% to ~1.2%, and ~0.01% to ~0.001%, respec-
tively. Again, this reduction was not associated with reduced numbers of this organisms
(1.29 × 106 compared to 4.25 × 106 with C. albicans for A. naeslundii and 1.99 × 103 vs.
4.19 × 103 plus C. albicans for L. casei). All mean CFE/mL and compositional changes are
documented in Table 2.
Within the ST biofilm (Figure 2C), all bacterial genus or species increased in CFE/mL
in the presence of C. albicans. Compositionally, V. dispar and Streptococci species (S. mitis, S.
oralis and S. intermedius) remained the main constituents of the biofilm after the inclusion of
C. albicans, although a reduction in the proportion of Streptococcus species was seen (~79.3%
compared to ~89.9%, for V. dispar, and ~14.40% compared to ~3.26%, for Streptococci,
respectively). Meanwhile, A. naeslundii (~4.76% to ~1.55%) and A. actinomycetemcomitans
(~1.56% to ~1.25%) were both reduced in proportion following addition of C. albicans. The
Socransky red complex constituent of P. gingivalis was present at low quantities, as expected
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in a periodontal biofilm [40]. with the organism increasing ten-fold in proportion and
100-fold in concentration after the addition of C. albicans (0.001% and 1.23× 102 CFE/mL in
bacterial-only biofilms, compared to 0.011% and 1.74× 104 CFE/mL for Candida-containing
biofilms, respectively). The bridging organism F. nucleatum also showed an increase from
~0.01% to ~0.05% in the presence of C. albicans, including a ~2-fold increase in bacterial
numbers (2.80 × 103 compared to 5.12 × 103 CFE/mL). All CFE/mL and % changes are
shown in Table 2. Overall, the results indicated that addition of C. albicans to the biofilm
increased the bacterial load in both oral biofilm models. Changes associated with the
composition showed a more diverse biofilm in HT biofilm, whilst ST biofilms were still
dominated by V. dispar and Streptococcus spp. An increase in the periodontal pathogens
such as F. nucleatum and P. gingivalis in the ST biofilms indicate a more diverse consortium
with the inclusion of C. albicans.
Table 2. Mean colony forming equivalent per mL and average percentage composition for each genus or species in the
hard and soft tissue biofilms. CFE/mL and percentage composition shown for each genus or species as an average of 9
independent biofilms (n = 3 from 3 separate experiments). All numbers shown in the table have been rounded to the first
significant decimal place, where possible.
Genus
or Species
Mean CFE/mL and Percentage Composition (%)
Hard Tissue Soft Tissue
− C. albicans + C. albicans − C. albicans + C. albicans
CFE/mL % CFE/mL % CFE/mL % CFE/mL %
C. a n/a n/a 4.60 × 107 12.81 n/a n/a 6.08 × 106 4.00
Strep 7.12 × 106 43.10 1.04 × 108 29.00 2.87 × 106 14.40 4.96 × 106 3.26
A. n 1.29 × 106 7.82 4.25 × 106 1.18 9.50 × 105 4.76 2.36 × 106 1.55
V. d 8.10 × 106 49.05 2.03 × 108 56.63 1.58 × 107 79.27 1.36 × 108 89.87
F. n 2.91 × 103 0.02 1.38 × 106 0.38 2.80 × 103 0.014 5.12 × 103 0.05
L. c 1.99 × 103 0.01 4.19 × 103 0.001 n/a n/a n/a n/a
P. g n/a n/a n/a n/a 1.23 × 102 0.001 1.74 × 104 0.011
P. i n/a n/a n/a n/a 5.49 × 102 0.003 5.12 × 103 0.003
A. a n/a n/a n/a n/a 3.11 × 105 1.56 1.90 × 106 1.25
3.2. Scanning Electron Microscopy Visualization of Oral Biofilm Models with or without C. albicans
Next, the ultrastructures of the oral biofilm models were assessed using scanning
electron microscopy (SEM). SEM imaging highlighted the change in architecture, particu-
larly in HT biofilms wherein C. albicans was included (Figure 3). In HT biofilms without C.
albicans (Figure 3A), the cells were clustered into complexes that were spaced out across the
coverslip, in stark contrast to the network of cells and ECM within HT biofilms, including
a fungal element (Figure 3B). ST biofilms (Figure 3C) demonstrated a complex and dense
biofilm without the addition of C. albicans. Although it is clear from the bacterial load
that there was still a small increase in bacterial numbers (as shown in Figure 2A), SEM
pictures were comparable between the biofilms plus or minus C. albicans for the ST biofilms
(Figure 3C,D). Nevertheless, there were clear physical interactions between the microbiota
and the yeast and/or hyphae of the C. albicans in both models (indicated by the red arrows
in the insets of Figure 3B,D).
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3.3. Change in Pathogenic Biomarkers in Oral Biofilm Models in the Presence and Absence of C. albicans
Next, a range of biomarkers for virulence were assessed to deter ine if fungal addition
to the oral biofilm models altered the pathogenicity of the biofilms. The pHs of the oral
cavity and saliva have been established as markers for disease [57,58], whilst ROS and
protease production may be linked to toxic metabolites and virulence [59,60]. Therefore,
these markers were assessed in the two biofilm models (Figure 4). The pHs of both biofilm
supernatants were significantly increased to a more neutral value in the presence of C.
albicans (Figure 4A). HT biofilm supernatants had an average pH value of 5.8, which
increased to 7.4 and ST biofilm supernatants increased by 1.5 units to a pH of 6.5 following
inclusion of C. albicans. This was suggestive that the presence of a fungal element acts as a
buffer to increase the environmental pH, which is in line with previous observations for C.
albicans [61]. To corroborate these observations in pH measurements, lactate concentration
was also determined. The modulation of lactate production by the microbial consortia
is a common mechanism to generate acidic environments, which is likely occurring in
the cariogenic HT biofilm. Results from Figure 4B demonstrate that in both HT and ST
biofilms, C. albicans reduced lactate content in the supernatant collected from the biofilms.
A 2-fold reduction was noted from HT biofilms, while a 14-fold decrease was apparent in
ST biofilms following addition of C. albicans.
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Figure 4. Assessment of functional biomarkers in hard tissue (HT) and soft tissue (ST) biofilms with or without C. albicans.
Supernatants were collected on the final day of maturation and stored at −80◦ C until required. Prior to freezing, pH was
tested using a microprobe (A). Lactate assay kit was used to determine lactate content (B). Superoxide dismutase assay
was carried out using WST-1 tetrazolium salt and xanthine as per assay instructions with a 100× sample dilution applied
(C). Protease activity was assessed using a fluorescent protease detection kit. Trypsin was used as a standard curve as per
manufacturer’s instructions (D). Data represented as mean ± SD, sampled in triplicate from three independent experiments.
A Mann–Whitney t-test was used throughout to assess significant differences between the means of models with or without
C. albicans (*** p < 0.001).
ROS within the oral cavity can be a marker for inflammation and cell damage [62],
and therefore the activity of enzyme superoxide dismutase was determined in the biofilm
supernatants. Interestingly, in HT biofilms, Candida decreased superoxide dismutase
activity 5-fold, whilst conversely, the presence of C. albicans increased the activity in the ST
biofilms 4-fold (Figure 4C). Finally, similarly to ROS, protease activity can be an indicator
of a dysbiotic biofilm [63]. Figure 4D shows an increase in protease activity in HT biofilms
when C. albicans is present, with a 9-fold increase in protease activity. In contrast, quantities
remained low in both ST biofilms with a small 1.6-fold increase in those biofilms with C.
albicans.
Figure 5, panels A and C, showed that the most effective treatment was CHX, which
reduced the metabolic activity of both biofilms tested, irrespective of the inclusion of
Candida. The metabolic activities of the remaining biofilms were comparable to untreated
controls following treatment with EDTA, potassium iodine (KI) or miconazole (MCZ), even
following the addition of C. albicans. Post-treatment with CHX, metabolic activity was
reduced by about 50% compared to the control in HT (Figure 5A) and ~70% in the ST
biofilms (Figure 5C) regardless of inclusion of a fungal element, which was a significant
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reduction when compared to each individual control (p < 0.01, p < 0.001). In contrast,
average metabolic activity in the biofilms following treatments from EDTA, KI and MCZ
showed small changes from the control, but not significantly different. For the CHX-treated
ST biofilm minus C. albicans, significantly greater biomass was detected when compared to
the controls, suggestive of possible artificial CV staining of CHX precipitate within these
biofilms (p < 0.001). There were no significant differences in susceptibility profiles of the
HT biofilms to the treatments compared to the untreated controls (Figure 5B). Interestingly,
ST biofilms treated with EDTA were the only treated biofilm to become more susceptible to
disruption compared to the UT following the inclusion of C. albicans (Figure 5D; # p < 0.05),
while all other treatments remained comparable to the control. Overall, this highlights a
similarity in the treatment responses of the biofilms, which following the inclusion of C.
albicans, did not create a more resilient or susceptible biofilm in vitro.
Microorganisms 2021, 9, x FOR PEER REVIEW 14 of 23 
 
 
manufacturer’s instructions (D). Data represented as mean ± SD, sampled in triplicate from three independent experi-
ments. A Mann–Whitney t-test was used throughout to assess significant differences between the means of models with 
or without C. albicans (*** p < 0.001). 
Figure 5, panels A and C, showed that the most effective treatment was CHX, which 
reduced the metabolic activity of both biofilms tested, irrespective of the inclusion of Can-
dida. The metabolic activities of the remaining biofilms were comparable to untreated con-
trols following treatment with EDTA, potassium iodine (KI) or miconazole (MCZ), even 
following the addition of C. albicans. Post-treatment with CHX, metabolic activity was re-
duced by about 50% compared to the control in HT (Figure 5A) and ~70% in the ST bio-
films (Figure 5C) regardless of inclusion of a fungal element, which was a significant re-
duction when compared to each individual control (p < 0.01, p < 0.001). In contrast, average 
metabolic activity in the biofilms following treatments from EDTA, KI and MCZ showed 
small changes from the control, but not significantly different. For the CHX-treated ST 
biofilm minus C. albicans, significantly greater biomass was detected when compared to 
the controls, suggestive of possible artificial CV staining of CHX precipitate within these 
biofilms (p < 0.001). There were no significant differences in susceptibility profiles of the 
HT biofilms to the treatments compared to the untreated controls (Figure 5B). Interest-
ingly, ST biofilms treated with EDTA were the only treated biofilm to become more sus-
ceptible to disruption compared to the UT following the inclusion of C. albicans (Figure 
5D; # p < 0.05), while all other treatments remained comparable to the control. Overall, this 
highlights a similarity in the treatment responses of the biofilms, which following the in-
clusion of C. albicans, did not create a more resilient or susceptible biofilm in vitro. 
 
Figure 5. Treatment outcomes of hard and soft tissue biofilms with or without C. albicans. After maturation, biofilms were 
treated with 0.2% CHX, 4% EDTA, 1% KI or 40 µg/mL MCZ for 10 min at room temperature. Alamar blue™ dye was used 
to assess metabolic activity was calculated against an untreated control (HT biofilm (A) and ST biofilm (C)). Data represent 
mean ± SD, carried out in triplicate in three independent experiments. A Mann–Whitney t test was carried out on the raw 
metabolic activity data to assess significant differences between untreated (UT) and treated biofilms (## p < 0.01, ### p < 
0.001). Following metabolic assessment, biofilms were dried overnight at room temperature and biomass was determined 
via crystal violet staining (HT biofilm (B) and ST biofilm (D)). A dotted black line has been drawn to illustrate the average 
results of the UT control—C. albicans, and a black solid line entered to show the UT control + C. albicans. Data represent 
mean ± SD, carried out in triplicate or quadruplicate on three independent experiments (a total of 11 replicates from 3 
Figure 5. Treatment outcomes of hard and soft tissue biofilms with or without C. albicans. After maturation, biofilms were
treated with 0.2% CHX, 4% EDTA, 1% KI or 40 µg/mL MCZ for 10 min at room temperature. Alamar blue™ dye was used
to assess metabolic activity was calculated against an untreated control (HT biofilm (A) and ST biofilm (C)). Data represent
mean ± SD, carried out in triplicate in three independent experiments. A ann– hitney t test was carried out on the raw
metabolic activity data to assess significant differences between untreated (UT) and treated biofilms (## p < 0.01, ### p <
0.001). Fol o ing etabolic assess ent, biofilms were dried overnight at room te perature and biomas was determined
via crystal violet staining (HT biofilm (B) and ST biofilm (D)). A dotted black line has been drawn to illustrate the average
results of the UT control—C. albicans, and a black solid line entered to show the UT control + C. albicans. Data represent
mean ± SD, carried out in triplicate or quadruplicate on three independent experiments (a total of 11 replicates from 3
separate experiments). A Mann–Whitney t test was used to compare significant differences between UT biofilms and treated
biofilms (# p < 0.05, ### p < 0.001, *** p < 0.001).
3.4. Bacterial Load Following Treatment in Oral Biofilm Models with or without C. albicans
Finally, the bioburden of bacteria and fungi were assessed following treatment using
qPCR analyses. For all treatments, no significant difference was found when comparing
bacterial load (16S) to the respective untreated controls in either biofilm model (Figure 6A,C,
white bars). Similar results for bacterial counts were observed when C. albicans was
included in the models (ns, p > 0.05; Figure 6A,C, grey bars). In both biofilm models,
irrespective of treatment, log increases of between ~0.5 and ~1.5 units were seen in bacterial
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counts following inclusion of C. albicans (Figure 6B,D). No differences were also seen when
comparing the fungal counts (18S) following treatment, with C. albicans maintaining a level
of ~3–5 × 107 CFE/mL for HT, and ~3–6 × 107 CFE/mL for ST irrespective of treatment
type (ns, p > 0.05). All average CFE/mL values for each biofilm with or without treatment
are shown in Table 3. Taken together, the qPCR data indicated that the bacterial load was
not affected by treatment with a variety of different agents following incorporation of C.
albicans, suggesting that the fungal element did not convey protection for the microbiota
against the variety of agents.
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growth and removal of the biofilm from the microtiter plate, DNA was extracted using the QIAamp DNA Mini Kit, and
bacterial load was assessed using 16S PCR. Data represent mean ± SD, experiment carried out in duplicate from three
indep ndent experiments. The to al bacterial load (shown as col ny forming equivalent (CFE) per mL) is shown for HT
biofilms (A) and ST associated biofilms (C). The white bars are indicative of bacterial-only biofilms, whilst grey bars show
the biofilms containing C. albicans. The fungal loads (quantified using 18s qPCR) of the biofilms were also assessed in the
C. albicans-containing biofilms and total CFE/mL counts are documented in Table 3. Log increase, HT, caries associated
biofilms (B) and ST associated biofilms (D) of biofilms with or without C. albicans. No significant differences were observed
between untreated and treated samples using a Mann–Whitney t test.
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Table 3. Average colony forming equivalent counts for total bacteria and fungi in the two biofilm
models following treatment. The mean CFE/mL for each biofilm was calculated from an average of
9 independent biofilms (n = 3 from 3 separate experiments) following treatment with CHX, EDTA, KI
and MCZ compared to untreated controls.
Biofilm Treatment
Average CFE/mL
16S 18S
− C. a + C. a − C. a + C. a
ST
UT 1.77 × 108 9.96 × 108 n/a 6.08 × 106
CHX 4.74 × 108 1.30 × 109 n/a 4.31 × 106
EDTA 2.91 × 108 7.66 × 108 n/a 3.91 × 106
KI 4.13 × 108 8.46 × 108 n/a 3.32 × 106
MCZ 2.79 × 108 5.60 × 108 n/a 3.21 × 106
HT
UT 6.00 × 107 1.59 × 109 n/a 4.60 × 107
CHX 2.02 × 108 2.59 × 109 n/a 4.21 × 107
EDTA 4.91 × 107 1.04 × 109 n/a 3.34 × 107
KI 9.84 × 107 1.18 × 109 n/a 3.11 × 107
MCZ 6.13 × 107 1.36× 109 n/a 3.52 × 107
4. Discussion
Candida albicans is known as an opportunistic pathogen which colonizes many different
sites of the human body, with an ability to cause severe disease through candidiasis
in the immunocompromized [64]. C. albicans also has the ability to form biofilms on
a range of surfaces in a medical setting, such as indwelling medical devices [65], and
has also been found as a potent colonizer of various oral mucosal sites [66,67]. With
known mortality rates of up to 60% in candidemia patients and studies highlighting the
pathogenic nature of Candida biofilms [68,69], from a clinical standpoint, Candida infections
and associated biofilms are viewed as highly problematic. Furthermore, in the context of
biofilm research, the pathogenic mechanisms of many microbial diseases are now often
viewed as interkingdom and polymicrobial in nature [70,71]. As such, it is perhaps no
surprise that our understanding of fungal–bacterial interactions continues to progress,
particularly in the oral cavity whereby C. albicans specifically has been implemented as
potential “active accomplice” in different oral infections [11]. Hence this study aimed
to investigate the biofilm “profiles” and/or pathogenic “signatures” of two oral biofilm
models following incorporation of C. albicans.
Firstly, and perhaps unsurprisingly, results showed that metabolic activity and biomass
were increased when C. albicans was included within the biofilms (Figure 1). Metabolic
activity quantified via Alamar blue™ assay is a measurement of the rate of respiration
in the reduction of resazurin to resorufin by electron acceptors such as NADPH and cy-
tochromes [72]. Crystal violet staining, commonly used in Gram staining techniques, binds
to the cell walls of bacteria and fungi, and lipopolysaccharides and DNA, both of which are
large components of the extracellular matrix (ECM) [73]. Metabolic activity and biomass
testing in biofilms in reality are crude measurements that can be useful when used with a
variety of other techniques. Hence, it is essential to note that growth rates differ between
organisms, and therefore metabolic output observations should be viewed with a certain
level of caution. As such, metabolic activity may not be representative of the whole biofilm,
but as an indicator of the fastest growing and thereby more metabolically active organism
present in the consortia. However, it can still be used as an inclusive measurement tool
with other techniques to assess changes in the biofilm environment [74,75]. Additionally,
CV staining does not differentiate between additional components of the biofilm (e.g.,
extracellular matrix and eDNA) and cells within the biofilm [73,76]. Nevertheless, results
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from these simple methodologies highlight that a thicker, more metabolically active biofilm
was formed in the presence of C. albicans.
From the results here, the increase in metabolic activity and biomass for biofilms
grown with C. albicans could be multifactorial and not simply caused by more cells being
present. Therefore, it was deemed pertinent to assess microbial cell numbers via qPCR.
For the CV observations, the size difference of C. albicans to bacteria may influence the
increase in CV values, with the average C. albicans cell being almost 150× larger than their
bacterial counterparts, and so it would be logical that an increase in CV was detected [15,17].
Alternatively, the elevated biomass may be caused by an increase in ECM production from
cells; studies have shown an increase in ECM production from bacteria in the presence
of C. albicans [77]. As a culmination of factors, the addition of C. albicans may also reduce
the amount of biofilm washed away during the CV experimental procedure, helping one
to retain a more robust and metabolically active biofilm in vitro. Indeed, C. albicans has
previously been shown to be a structural scaffold within dual-species biofilms [56]. This
may be an effect we observed in this study, particularly with the increase in bacterial load,
as shown in Figure 2, and confirmed through increased architecture in SEM images shown
in Figure 3, particularly in the HT biofilms. Ultimately, it could be that a robust biofilm
containing C. albicans would provide a better representation of the polymicrobial nature
of the biofilms in the oral cavity, which may allow for more appropriate and accurate
routine testing to be undertaken in vitro. At this juncture, it has been shown previously
that mechanical removal through brushing alongside therapeutic activity is required to
successfully manage these fungal–bacterial biofilms in vitro [38].
Alongside the increase in bacterial load there were compositional changes that ac-
companied the inclusion of C. albicans, as seen in Figure 2B,C. In HT biofilms, the main
components remain similar; however, S. mutans and L. casei decreased in proportion after
the addition of C. albicans, which may be a result of the increase in pH to a more neutral
environment in the presence of the fungi (Figure 4). It has been shown elsewhere that
C. albicans has the ability to neutralize an acidic environment, a process that will lead to
induction of the yeast-hyphal transition, an important virulence mechanism used by the
organism to promote survival and/or tissue invasion [61]. The presence of the remaining
organisms within this model, even following incorporation of C. albicans, was deemed
essential to include to provide a representative caries biofilm rather than focusing on S.
mutans as a single species, a limitation of previous studies given the polymicrobial nature
of the disease [78]. In ST biofilms, an increase in pathogens such as P. gingivalis was noted
following addition of the fungi; therefore, in a similar manner to the HT model, it would
allow a more appropriate biofilm to be used to study soft tissue diseases such as denture
stomatitis and periodontitis. As such the ST biofilm incorporates anaerobic bacteria rep-
resenting periodontitis and C. albicans in denture stomatitis alongside an interkingdom
biofilm representative of that seen in ecological niche of these diseases [19]. C. albicans has
been shown to generate hypoxic conditions in a biofilm microenvironment [79], which may
explain the elevated number of anaerobic pathogens, such as P. gingivalis and F. nucleatum
in the ST biofilms containing Candida. Overall, it could be argued that inclusion of any
fungal element into such a polymicrobial biofilm would cause composition changes, simply
due to the size and morphological phenotypes of such organisms. This, of course, raises the
question: “can all oral fungal species serve as keystone commensals?” Such a postulation
goes far beyond the remit of the current paper but definitely requires careful consideration
moving forward.
The link between acidic conditions in the oral cavity and dental caries onset is well
documented; however, periodontal biofilms have also been shown to acidic in nature [80].
As discussed above, C. albicans inclusion seemed to offer a buffering effect, as shown in
the pH increase with the value closer to neutral in the supernatants collected (Figure 4).
Such a buffering effect is not unheard of with C. albicans, an organism which prefers to
maintain a cytosolic pH range of between 5.8 and 9 [81]. Lactate and lactic acid are common
metabolites of oral bacteria, and often a dysbiosis in the utilization and production of these
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compounds can lead to disease [82]. Results showed here that lactate was reduced in
biofilms with C. albicans (Figure 4B). C. albicans is able to utilize lactate as a substrate to
produce an increased stress response and drug resistant properties [83]. Previous studies
have also shown that through ammonia production, C. albicans cells are able to self-regulate
pH to allow morphogenesis (the ability to shift from yeast to hyphae) and proliferation [61].
This rise in pH, likely through the regulation of lactate levels, may suggest that having C.
albicans within an oral biofilm may provide a protective, more pH neutral environment
within this model. Such observations may have implications on studies interested in health
vs. disease models, whereby inclusion of C. albicans stabilizes the biofilm, making it more
habitable by health-associated organisms.
ROS such as superoxide anion (SOD) and hydrogen peroxide are essential metabolites
in cellular respiration; however, accumulation and failure to neutralize ROS leads to
oxidative stress and cell death [84]. In that capacity, SOD was tested for in the oral biofilm
models. Figure 4C shows that SOD is reduced in HT + C. albicans containing biofilms,
possibly indicating less reactive oxygen species are present within the environment. On
the contrary, ST biofilm + C. albicans showed an increase in SOD; this may have been due
to the facultative anaerobic bacteria (such as F. nucleatum, V. dispar, A. naeslundii and A.
actinomycetemcomitans) producing more SOD than aerotolerant species [85].
To assess overall hydrolytic qualities of the biofilm models, protease activity was
quantified (Figure 4D). C. albicans containing HT biofilm showed increased levels of pro-
tease activity when compared to the C. albicans lacking biofilm. C. albicans pathogenicity
depends on the secretion of proteinases to invade host cells through the damaging of cell
membranes, and so this increase may be directly linked to C. albicans’ presence [86,87].
In order to fully assess the implication of this, additional work carried out under a high
sugar environment would be required. Furthermore, these observations regarding protease
activity may simply be due to the increased microbial load within the biofilms containing C.
albicans. To investigate whether this was the case, experiments presented here would need
to be repeated with (1) heat-inactivated Candida or (2) mutated isolates lacking specific
protease genes (e.g., secreted aspartyl proteinase mutants).
Finally, to assess whether the inclusion of C. albicans affected the biofilms response to
treatments, the efficacies of different antimicrobials were tested. The antimicrobials chosen
represent a series of agents with different mode of actions and purposes, a gold-standard
mouthwash (CHX), irrigants (EDTA/KI) and an antifungal agent (MCZ). Following treat-
ment, the metabolic activity, biomass and fungal/bacterial load of each biofilm were
assessed. Such parameters were chosen for analyses as previous evidence has indicated
that biofilm viability and metabolic activity are reduced following short-term treatment
with certain therapeutics (e.g., CHX) [88–90], whilst others have shown components such
as EDTA can destabilize and degrade extracellular matrix [91], possibly leading to de-
tachment of the biofilm and loss of overall bioburden. From the actives tested, CHX was
the only agent which significantly reduced metabolic activity in comparison with the UT
control (Figure 5A,C), although this reduction did not equate to detachment since biomass
data and bacterial load data are not decreased and similar to the UT control (Figure 5B,D).
Furthermore, the efficacy of CHX did not change in biofilms with or without C. albicans.
EDTA significantly reduced the biomass of the Candida-containing biofilm, suggestive that
the antimicrobial is effective against the fungal element, which is in line with previous
observations [92,93]. The lack of reduction in metabolic activity, biomass and/or cell num-
ber for any of the other treatments tested highlights the importance of treatment time and
the potential adjunctive use of mechanical disruption alongside antimicrobial therapies,
even in the context of in vitro studies. Standard overnight incubations usually employed in
minimum biofilm eradication studies may overestimate the effectiveness of the active [94]
and so a short incubation time was favored for this study. It may be that longer incubation
times would result in differences in tolerance levels of the biofilms to such therapeutics
following inclusion of C. albicans. It should also be noted that only normal qPCR, and
not live/dead qPCR, was used to quantify the bacterial and fungal load in the models
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following treatment. This live/dead methodology has been used with great effect to assess
the level of “viability” of oral microorganisms in plaque samples and in vitro biofilm mod-
els [38,44,95]. Therefore, it could be that no changes were observed in the total bacterial
or fungal load in this study, but there may have been reductions in the number of viable
cells present in the biofilm (which could corroborate with the metabolic activity changes
particularly for CHX treatment for example). It is not uncommon for dead microbial cells
to remain in the biofilm even following treatment [88,89,96]. Therefore, this poses the
question: “does the biofilm require some degree of mechanical disruption for sufficient
removal of dead and viable cells?” Indeed, in the case of most oral diseases of microbial
origin, particularly for dental caries and periodontitis, the primary aim for clinicians is
physical debridement of the biofilm, before administering antimicrobials to prevent the
regrowth of microorganisms. This ultimately highlights the need for mechanical removal
of biofilms in vitro to truly provide realistic model systems as shown with previous studies
conducted [38,97]. Sherry et al. (2016) highlighted the importance of adjunctive therapies
of biofilm testing in vitro. In this study, the 11- species biofilm used here (ST) was subject
to cleaning regimes involving a denture cleansing treatment. Mechanical disruption by
brushing alone was not sufficient to reduce bioburden on the denture substrates, whereby
only when used in conjunction with the denture cleanser was significant reductions in
viable microbial cells observed [38]. Future studies must consider using these “disrupt and
inhibit” experiments with such in vitro oral biofilm model systems.
From this work it can be concluded that future studies should consider incorporation
of a fungal element to fully encompass the polymicrobial nature of the oral cavity. The
emerging postulations that C. albicans may serve as a “keystone commensal” in multispecies
oral communities highlights its importance in the context of oral health (and disease) [15].
This study, to the authors knowledge, was the first to truly assess whether C. albicans
serves as a “keystone” component in oral biofilm models in vitro. From the data, the
importance of including Candida in such biofilm models is attributed to a more robust
structure of the mixed species consortia, while not affecting the tolerance of the biofilm to
short-term exposure of conventional oral therapeutics. Indeed, further studies are required
to truly understand what role C. albicans, and other fungal inhabitants, play in homeostasis
of the oral cavity, and we hope this study will provide a platform for further research
into said phenomenon. In the long term, inclusion of such an organism in otherwise
bacterial-only biofilms should hopefully generate a more applicable model system for
testing conventional and/or novel therapeutics.
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